Related Experiment Video

Updated: Aug 18, 2026

Increasing Pulmonary Artery Pulsatile Flow Improves Hypoxic Pulmonary Hypertension in Piglets
08:08

Increasing Pulmonary Artery Pulsatile Flow Improves Hypoxic Pulmonary Hypertension in Piglets

Published on: May 11, 2015

Nebulized nitroglycerin in children with pulmonary hypertension secondary to congenital heart disease

H A Omar1, F Gong, M Y Sun

  • 1University of Kentucky, Lexington, USA.

The West Virginia Medical Journal
|April 24, 1999
PubMed

Insights

Nebulized nitroglycerin effectively reduced pulmonary artery pressure in children with congenital heart disease. This treatment offers a safe, inexpensive, and accessible option for severe pulmonary hypertension.

Area of Science:

  • Pediatric Cardiology
  • Respiratory Medicine
  • Pharmacology

Background:

  • Pulmonary hypertension (PH) is a significant cause of mortality in children, even with advanced treatments.
  • Inhaled nitric oxide shows efficacy in some PH cases, prompting investigation into alternative inhaled therapies.
  • Congenital heart disease (CHD) is a common cause of PH in pediatric populations.

Purpose of the Study:

  • To evaluate the efficacy and safety of nebulized nitroglycerin for treating severe pulmonary hypertension in children with CHD.
  • To compare the effects of nebulized nitroglycerin versus placebo (normal saline) on hemodynamic parameters in pediatric PH patients.

Main Methods:

  • A randomized, placebo-controlled study involving four children (6-72 months) with severe PH secondary to CHD.
  • Patients received nebulized normal saline (placebo) followed by nebulized nitroglycerin (20 mcg/Kg).
  • Hemodynamic parameters, including pulmonary artery pressures and blood pressure, were measured during cardiac catheterization.

Main Results:

  • Nebulized nitroglycerin significantly reduced systolic pulmonary artery pressure (68 to 53 mmHg, P=0.006) and mean pulmonary artery pressure (47 to 38 mmHg, P=0.005).
  • No significant changes were observed with placebo administration.
  • Heart rate and blood pressure remained stable, indicating a favorable safety profile.

Conclusions:

  • Nebulized nitroglycerin presents a potentially effective, safe, and inexpensive treatment for severe pulmonary hypertension in children with CHD.
  • This method may be particularly valuable in resource-limited settings where advanced therapies are unavailable.
  • Further research is warranted to confirm these findings in larger pediatric cohorts.

More Related Videos

A Minimally Invasive Method for Intratracheal Instillation of Drugs in Neonatal Rodents to Treat Lung Disease04:21

A Minimally Invasive Method for Intratracheal Instillation of Drugs in Neonatal Rodents to Treat Lung Disease

Published on: August 4, 2021

A Novel Inhalation Mask System to Deliver High Concentrations of Nitric Oxide Gas in Spontaneously Breathing Subjects05:46

A Novel Inhalation Mask System to Deliver High Concentrations of Nitric Oxide Gas in Spontaneously Breathing Subjects

Published on: May 4, 2021

Related Concept Videos

Antihypertensive Drugs: Vasodilators01:23

Antihypertensive Drugs: Vasodilators

Vasodilators, primarily affecting the smooth muscles within arterial and venous walls, are commonly used for hypertension treatment. Medications such as minoxidil and hydralazine primarily target arteries and arterioles, while sodium nitroprusside acts on arterioles and venules. Minoxidil, functioning as a prodrug, is metabolized by hepatic sulfotransferase into its active form, minoxidil sulfate, after oral administration. This metabolite binds to the sulfonylurea receptor (SUR) component of...
Antianginal Drugs: Nitrates and β-Blockers01:16

Antianginal Drugs: Nitrates and β-Blockers

In cardiovascular health, antianginal drugs combat angina pectoris — a condition marked by chest pain owing to diminished blood flow to the heart.
Organic nitrates,  such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow. Administered...
Pulmonary Hypertension: Classification and Pathogenesis01:30

Pulmonary Hypertension: Classification and Pathogenesis

Pulmonary hypertension (PH) is a severe health condition in which the mean pulmonary arterial pressure increases to 25 mmHg or more, even when the body is at rest. This high pressure in the blood vessels that transport blood from the heart to the lungs can cause various symptoms, including shortness of breath, can lead to right heart failure, and significantly affect the overall quality of life.
There are various classifications for PH, each relating to different underlying causes and also...
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
Drug Delivery: Enteral Route01:18

Drug Delivery: Enteral Route

The enteral drug administration involves three primary routes: oral, sublingual, and buccal. Oral ingestion is the most prevalent, safe, economical, and convenient method for drug administration. However, it has certain drawbacks, including limited absorption due to the drug's low water solubility or poor membrane permeability, possible emesis from GI mucosa irritation, destruction of drugs by digestive enzymes or low gastric pH, and irregular absorption along with food or other drugs.
Drugs in...